Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision indicator updated from v3.4.1 to v3.4.2 appears in the page footer. No study data, sections, or functionality were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check30 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page now shows Revision: v3.3.4 in the footer, and Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check73 days agoChange DetectedLocations section added with state-level site listings (Florida, Georgia, Indiana, Kansas, Louisiana, Missouri, New York, North Carolina, Rhode Island, South Carolina, Texas, Utah). Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure element.SummaryDifference1%

- Check103 days agoChange DetectedMinor editorial updates: the Publications disclaimer was reworded from 'study results' to 'results of the study', and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.